Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-00356231 is an experimental small molecule inhibitor of matrix metalloproteinase 12 (MMP‑12). It is a non-peptidic, non-zinc chelating ligand that selectively inhibits MMP‑12 with an IC50 of approximately 1.4 μM. At higher concentrations, it may also inhibit other matrix metalloproteinases. The compound belongs to the phenylpyridine class and was developed as a potential therapeutic for conditions involving MMP‑12 activity, such as inflammatory or degenerative diseases[1][2][3][9]. Its chemical formula is C25H20N2O3S and its CAS number is 766536‑21‑4[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PF-00356231.